- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02940990
SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations
Study Overview
Status
Detailed Description
Lung cancer is the leading cause of cancer death. Forty percent of patients are diagnosed as metastatic lung cancer, and about 50% of them are pan-negative for driver mutations. The median overall survival(OS) for these patients is 11 months, and maintenance therapy can only prolong 2 months of OS. The NCCN guidelines recommend 4-6 cycles of chemotherapy with or without maintenance chemotherapy.
Published data showed that radiotherapy modulates tumor phenotypes, enhances antigen presentation and tumor immunogenicity. The regression of out-field lesions was termed as "abscopal effect". The combination of radiotherapy with immunotherapeutic agents may promote the host anti-tumor immune response and increase the rate of abscopal effect.Published data showed that abscopal effect appeared in 20%-30% patients with metastatic malignant tumors who were treated with the combination of SBRT and GM-CSF.
The investigators evaluate the efficacy of the combination of SBRT and GM-CSF in the multi-metastatic NSCLC participants who are pan-negative for driver mutations. Patients enrolled will be randomized into two groups. The control group will receive the standard regimen as NCCN recommends. The experimental group will receive both the standard chemotherapy and the extra SBRT to primary lesions or metastatic lesions combined with GM-CSF. The investigators compare progress free survival(PFS) of the two groups.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China
- Shanghai Chest Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically proven non-small-cell lung cancer.
- Stage IV according to UICC stage system(version 7,2009).The number of metastatic lesions>5
- Pan-negative for driver mutations including EGFR ALK ROS1 c-MET
- At least Three evaluable lesions among which at least two must be suitable for SBRT.
- ECOG performance status 0-2.
- Expected lifespan ≥3 months.
- No brain metastasis in MRI.
- No liver metastasis in abdominal CT or MRI.
- No malignant pleural effusion or pericardial effusion from chest CT and/or pathology.
- Stable lab values: Hematological:
Absolute neutrophil count (ANC) ≥1.5×109/L, Platelets ≥100×109/L, Hemoglobin ≥9 g/dL Renal: Creatinine OR Measured or calculated creatinine clearance (CrCl) (glomerular filtration rate [GFR] can also be used in place of creatinine or CrCl) ≤1.5× the upper limit of normal (ULN) OR ≥60 mL/min for patient with creatinine levels >1.5× institutional ULN Hepatic: Total bilirubin ≤1.5×ULN OR Direct bilirubin ≤ULN for patients with total bilirubin levels >1.5×ULN, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN OR ≤5×ULN for patients with liver metastases ,globulin≥20 g/L, albumin≥30 g/L.
- Able to understand and give written informed consent and comply with study procedures.
Exclusion Criteria:
- Any unstable systemic disease, including active infection, uncontrolled high blood pressure, unstable angina, newly observed angina pectoris within the past 3 months, congestive heart failure (New York heart association (NYHA) class II or higher), myocardial infarction onset six months before included into the group, and severe arrhythmia, liver, kidney, or metabolic disease in need of drug therapy.
- Previously diagnosed with immunodeficiency disease.
- Human immunodeficiency virus (HIV) infection.
- Women in pregnancy or lactation .
- Patients with mental illness, considered as "can't fully understand the issues of this research".
- other Cancer history.
- Histologically confirmed small cell carcinoma or other non NSCLC compositions in the cancer tissue.
- Brain metastasis or liver metastasis or malignant pleural effusion or pericardial effusion.
- Allergy of rhGM-CSF and its accessories.
- Contraindications to GM-CSF treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Group A
Participants in the Group A will receive 4-6 cycles of standard two-drug chemotherapy.
After that, clinical observation or maintenance chemotherapy will be given.
|
two-drug regimen
|
Experimental: Group B
Participants in the Group B will also receive 4-6 cycles of standard two-drug chemotherapy.
However, they will receive an additional treatment of SBRT to primary lesions or metastatic lesions combined with GM-CSF.
|
two-drug regimen
SBRT and GM-CSF 125ug/m2 for 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progress Free Survival (PFS)
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of treatment-related adverse events
Time Frame: 2 years
|
2 years
|
Overall Survival (OS)
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, Demaria S, Formenti SC. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015 Jul;16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6. Epub 2015 Jun 18.
- Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016 Aug;13(8):516-24. doi: 10.1038/nrclinonc.2016.30. Epub 2016 Mar 8.
- Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):293-5. doi: 10.1016/j.ijrobp.2012.03.017. Epub 2012 May 5.
- Daly ME, Monjazeb AM, Kelly K. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Dec;10(12):1685-93. doi: 10.1097/JTO.0000000000000686.
- Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016 Jan-Feb;40(1):25-37. doi: 10.1016/j.currproblcancer.2015.10.001. Epub 2015 Oct 9.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Folic Acid Antagonists
- Gemcitabine
- Docetaxel
- Carboplatin
- Etoposide
- Paclitaxel
- Cisplatin
- Albumin-Bound Paclitaxel
- Vinorelbine
- Pemetrexed
Other Study ID Numbers
- SCHLC007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
TYK Medicines, IncRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingStage II-III Non-small Cell Lung CancerChina
-
Tianjin Medical University Cancer Institute and...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingResectable Locally Advanced Non-small Cell Lung CancerChina
-
AstraZenecaRecruitingBiliary Tract CancerFrance, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruitingNon Small Cell Lung Cancer
-
Shanghai Chest HospitalUnknownRadiotherapy | Non-small Cell Lung Cancer Stage IIIAChina
-
Shanghai Chest HospitalFudan University; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsUnknownRadiotherapy | Non-small Cell Lung Cancer Stage IIIAChina
-
PfizerCompletedNeoplasmsPoland, United States, Spain
-
New Mexico Cancer Care AllianceGenentech, Inc.TerminatedCarcinoma, Non-Small-Cell LungUnited States
-
AstraZenecaActive, not recruitingNon Small Cell Lung Cancer NSCLCPoland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
-
AstraZenecaActive, not recruitingNon Small Cell Lung Carcinoma NSCLCPoland, Taiwan, Thailand, Vietnam, United States, Korea, Republic of, Hungary, Russian Federation, Turkey, China, Australia, Netherlands